EUCTR2004-002836-25-GB进行中（未招募）不适用
A Phase IIa Study To Investigate The Effects of AER 001on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration. - N/A
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult males and females > 18 years.
- •Subjects who if female, are using medically acceptable methods of contraception.
- •Subjects who have a pre study medical history, physical examination, 12 Lead ECG acceptable to the investigator.
- •Subjects who have clinical laboratory tests within the reference ranges or clinically acceptable to the investigator.
- •Subjects who are negative for HbsAg, hepatitis C antibody and HIV II and I test at screening.
- •Subjects who are negative for drugs of abuse and alcohol tests at screening and admission.
- •Regular or PRN use treatment of ß agonists.
- •Positive response on screening to a skin prick test.
- •Subjects who respond < 8 mg / mL on the methacholine challenge.
- •Subjects, who on the Allergen challenge, have a PC25 on allergen and exhibit a late phase response (>or = 10% between 4-10h) following the allergen challenge.
- •Subjects who have a FEV1 >70% of predicted.
- •Have not received steroid treatment in the prior month.
- •Subjects who are non-smokers for at least 3 months prior to screening.
- •Have a < 10 pack year history.
- •Satisfies the Global Initiative in Asthma (GINA, 2002) definition of asthma or have been on treatment for asthma.
- •Subjects with stable, adequately treated medical conditions may be enrolled provided the Principal Investigator does not consider their study participation to place them at increased risk of adverse events. Subjects should continue their concomitant treatments without change during the study.
- •Subjects who are able and willing to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Subjects who do not conform to the above inclusion criteria.
- •? Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders. Which would preclude antigen challenge
- •? Subjects who have a clinically relevant surgical history. Which would preclude antigen challenge
- •? Subjects who have a clinically relevant family history. Which would preclude antigen challenge
- •? Subjects who have a history of relevant drug hypersensitivity.
- •? Subjects who have a history of alcoholism.
- •? Subjects who have a history of drug abuse.
- •? Subjects who consume more than 28 units of alcohol a week.
- •(unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer)
- •? Subjects who have a significant infection or known inflammatory process on screening.
- •? Subjects who have acute gastrointestinal symptoms at the time of screening and/or admission (e.g. nausea, vomiting, diarrhoea, heartburn)
- •? Subjects who have an acute infection such as influenza at the time of screening and/or admission.
- •? Female subjects who are not using an acceptable method of contraception.
- •? Subjects who have used prescription drugs within 7 days of first dosing, unless agreed as non clinically relevant by the Principal Investigator and Sponsor. ? need
- •? Subjects who have used over the counter medication excluding routine vitamins but including mega dose vitamin therapy within 7 days of first dosing, unless agreed as non clinically relevant by the Principal Investigator and Sponsor. ?need
- •? Subjects who have used any investigational drug and /or participated in any clinical trial within 3 months of their first dosing.
- •? Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to first dosing (to review on a case by case basis).
- •? Subjects who cannot communicate reliably with the investigator.
- •? Subjects who are unlikely to co-operate with the requirements of the study.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2a Study To Investigate The Effects Of AER 002 On Mucociliary Clearance In Subjects With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)EUCTR2005-005044-40-GBAerovance, Inc20
进行中（未招募）
不适用
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.anemia of chronic disease in patients with cancerMedDRA version: 16.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10054310Term: Anemia of chronic diseaseSystem Organ Class: 100000004851EUCTR2012-001525-27-ATOXXON Pharma AG48
进行中（未招募）
1 期
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.EUCTR2012-001525-27-BGOXXON Pharma AG48
招募中
2 期
Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or LymphomaD63.0Anaemia in neoplastic diseaseAnemia of Chronic DiseaseDRKS00004366OXXON Pharma AG48
已完成
不适用
An open-label, single arm, Phase Ib/II study of AEB071 (a protein kinase C inhibitor) and everolimus (mTOR inhibitor) in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphomaDiffuse Large B Cell Lymphomanon-Hodgkin lymphoma10025320NL-OMON40516ovartis4